How to use the wet contact lens to treat a sore throat
Posted On July 6, 2021
When you’re feeling down and you want a quick fix for sore throat, wet contact lenses can help.
The FDA approved a drug that’s designed to help treat sore throat from the mouthparts of animals, but now a small, growing crop of scientists are finding the medication works just as well on people.
The drugs are made by Biogen and Bristol-Myers Squibb, and the companies say they are the only ones on the market that can treat sore throats from both mouth and throat parts.
If the medication does work, that could be an important advantage in treating sore throats that may occur more frequently or that require multiple treatments.
The new drug is called L-cysteine, which is an amino acid found in proteins.
L-cysine is a potent anti-inflammatory and antibiotic, and it has been used in clinical trials in people with Crohn’s disease, ulcerative colitis, rheumatoid arthritis and multiple sclerosis.
In the clinical trials, L-Cysteine has been shown to reduce inflammation, reduce infection and improve overall quality of life.
The drugs have also been shown in studies to reduce symptoms in people who have multiple sclerosis and Crohns disease.
The drug was approved for use in humans by the FDA in April and could be available in the United States in 2020.
The agency approved a small amount of the drug in early May.
Biogen and the FDA are also working on a larger trial of L-Cysine for use as a treatment for Crohnic disease and ulceration.
L-cystine is available as a powder, tablet, liquid or cream in the form of capsules, which Biogen hopes to sell as a separate product.
The FDA has not yet approved L-ocysteine for humans.
If it does, it could be used to treat sore nasal passages as well as other types of sore throat.
The American Academy of Dermatology, the American Academy for Dermatologic Surgery, the International Academy of Complementary and Alternative Medicine and the American College of Rheumatology have all endorsed L-cyclic L-lysine, said John R. Guglielmi, M.D., a professor of dermatology at the University of South Florida and the study’s lead author.
Dr. Gaglielmini said the drug could help people who suffer from sore throats with chronic infections or inflammatory diseases that cause sore throats.
It could also help people with dry, dry mouth, who are prone to sore throats, as well, he said.
People with severe allergic reactions to the drug have shown an increased rate of sore throats in the past.
But the FDA is still monitoring these people closely, Gaglilmi said.
If there are any serious side effects, people should be instructed to stop taking the drug, he added.
Elizabeth B. Korn, M.-D., the study co-author, said that the drug’s success rate was higher than expected because it was used in a small number of people.
But she cautioned that it could take some time for L-crystine to show up in more people.
People are getting a better understanding of its effectiveness, she said, adding that the results are encouraging.
The approval comes on the heels of other trials of L,Cystein, a synthetic compound developed by Biologics and Therapeutics.
That drug was originally approved in 2009 for use by cancer patients with aggressive melanoma and for ulcer patients with Crohns disease.
Biologi has said the compound is safe and has fewer side effects than L,cystein.
The company said it will begin marketing L,Cysin in the U.S. in early 2020.
The Drug Development and Manufacturing Advanced Research Center, an industry group for pharmaceutical companies, is helping Biologis develop L-Lysine.
The center is a division of the National Institutes of Health.
Biologics said the L-cylcysteinedrolidase gene is one of three genes in the lysine pathway.
The lysines are involved in the process that breaks down protein.
It’s the first synthetic lysion, the company said, and will have clinical benefits in people ages 12 to 70.
The National Institutes for Health and the National Cancer Institute are providing $3.5 million in funding for the trial, which will take place in the second quarter of 2020.
Biogen is also developing L,Lysin, and other new compounds, the companies said.
L,Cystine, Biologins first lysin and cysteine compound, and L,lysin.
Source: Biogen, Biogen Biologic.com, BiotechNews, Rheumatism article When it comes to sore throat treatments, there are several things you need to consider: When to use, how often, how much, how long, and whether to use it with other medications,